ANI Pharmaceuticals exceeded revenue expectations by 2.7% but fell short of earnings per share estimates. Forecast shows 8.8% revenue growth in the next 3 years, slightly lower than the industry average. A warning sign for ANI Pharmaceuticals was also highlighted.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing